- Home
- IMNM vs KYIV Comparison
IMNM vs KYIV Comparison
Compare IMNM & KYIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMNM | KYIV |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | United Arab Emirates |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMNM | KYIV |
|---|---|---|
| Price | $23.15 | $13.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $32.80 | $16.85 |
| AVG Volume (30 Days) | ★ 754.2K | 459.8K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,941,000.00 | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | $1,127.34 | $7.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.74 | $9.29 |
| 52 Week High | $27.65 | $16.48 |
Technical Indicators
Market Signals| Indicator | IMNM | KYIV |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 77.07 |
| Support Level | $19.23 | $11.15 |
| Resistance Level | $25.10 | $14.23 |
| Average True Range (ATR) | 1.10 | 0.50 |
| MACD | -0.15 | 0.17 |
| Stochastic Oscillator | 40.14 | 87.62 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
About KYIV Kyivstar Group Ltd.
Kyivstar Group Ltd is engaged in mobile communication.